课题基金 / 基金详情

Disordered Regulation of Wnt/beta-catenin Signaling in MPNST Development and Maintenance

Disordered Regulation of Wnt/beta-catenin Signaling in MPNST Development and Maintenance
MPNST 发育和维持中 Wnt/β-catenin 信号传导的紊乱调节
批准号:
8814072
负责人:
DAVID ANDREW LARGAESPADA
金额:
$49.03万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-15 至 2019-06-30

项目摘要

项目成果

DAVID ANDREW LARGAESPADA的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):我们进行了两个大的筛选,以确定驱动MPNST形成或维持的基因:1)在人MPNST细胞系中的shRNA筛选,以及2)在MPNST的小鼠模型中的基于睡美人(SB)转座子的插入突变筛选。这两种研究方法都发现Wnt/β连环蛋白调节的通路是MPNST维持的关键介质。初步数据证实,Wnt/β连环蛋白通路是维持MPNST所必需的,并且可以用小分子靶向。值得注意的是,我们确定了在MPNST中工作的ββ连环蛋白的多种激活机制。我们的建议集中在这些方面。目的1是基于我们的数据,证明了β连环蛋白破坏复合体的遗传或药物激活降低了β连环蛋白水平,减少了靶基因的表达,并抑制了MPNST细胞的生存和增殖。目的2是基于数据显示,由于转录与上游EIF3E基因融合,一些MPNSTs异位表达WNT/β连环蛋白激活剂R-响应蛋白2(RSPO2),这是我们最近在人类结直肠癌中发现的一种机制。目的3是基于揭示β连环蛋白靶基因PITX2在MPNST细胞生存中起关键作用的数据。我们的目标有两个:确定MPNST中β连环蛋白去调节的分子图景,并对在MPNST中干预WNT/β连环蛋白通路的关键靶点进行彻底的临床前评估,为在人类患者中进行有效的临床测试奠定基础。合作绩效机构建立了建立在互补技能和资源基础上的成功合作关系。大量的、正交的初步数据支持了这一建议的基本假设。
英文摘要
DESCRIPTION (provided by applicant): We carried out two large screens to identify genes driving MPNST formation or maintenance: 1) An shRNA screen in human MPNST cell lines, and 2) a Sleeping Beauty (SB) transposon- based insertional mutagenesis screen in a mouse model of MPNST. Both research approaches identified Wnt/β catenin-regulated pathways as critical mediators of MPNST maintenance. Preliminary data confirms that the Wnt/β catenin pathway is required for MPNST maintenance and can be targeted using small molecules. Remarkably, we identified multiple mechanisms of activation of β β catenin that operate in MPNST. Our proposal focuses on these. Aim 1 is based on our data demonstrating that genetic or pharmacological activation of the β catenin destruction complex reduce β catenin levels, reduce target gene expression, and inhibit cell survival and proliferation in MPNST. Aim 2 is based on data showing that some MPNSTs ectopically express a Wnt/β catenin activator R-spondin 2 (RSPO2) due to transcript fusion with the upstream EIF3E gene, a mechanism we recently identified in human colorectal cancer. Aim 3 is based on data revealing that the β catenin target gene PITX2 plays a critical role in MPNST cell survival. Our goals are two-fold: to define the molecular landscape of β catenin de-regulation in MPNST, and perform a thorough pre-clinical evaluation of critical targets for intervention in the Wnt/β catenin pathway in MPNST, setting the stage for effective clinical testing in human patients. The Co-PIs have established a successful collaborative relationship built on complementary skills and resources. Abundant and orthogonal preliminary data support the basic hypothesis of this proposal.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Integrated Immune Engineering for Poor Prognosis Cancers
  • 批准号:
    10700921
  • 项目类别:
  • 资助金额:
    $186.91万
  • 财政年份:
    2021
  • 负责人:
    DAVID ANDREW LARGAESPADA
  • 依托单位:
Integrated Immune Engineering for Poor Prognosis Cancers
  • 批准号:
    10270392
  • 项目类别:
  • 资助金额:
    $192.1万
  • 财政年份:
    2021
  • 负责人:
    DAVID ANDREW LARGAESPADA
  • 依托单位:
Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1
  • 批准号:
    10439480
  • 项目类别:
  • 资助金额:
    $57.74万
  • 财政年份:
    2020
  • 负责人:
    DAVID ANDREW LARGAESPADA
  • 依托单位:
Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1
  • 批准号:
    10653687
  • 项目类别:
  • 资助金额:
    $57.18万
  • 财政年份:
    2020
  • 负责人:
    DAVID ANDREW LARGAESPADA
  • 依托单位:
海外基金